Argenica Therapeutics (ASX:AGN) Debt-to-Asset : 0.00 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Argenica Therapeutics Debt-to-Asset?

Argenica Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.00 Mil. Argenica Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.00 Mil. Argenica Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was A$8.62 Mil. Argenica Therapeutics's debt to asset for the quarter that ended in Dec. 2023 was 0.00.

Argenica Therapeutics Debt-to-Asset Historical Data

The historical data trend for Argenica Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Argenica Therapeutics Debt-to-Asset Chart

Argenica Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

Debt-to-Asset

Argenica Therapeutics Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Argenica Therapeutics's Debt-to-Asset

For the Biotechnology subindustry, Argenica Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Argenica Therapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Argenica Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Argenica Therapeutics's Debt-to-Asset falls into.

Argenica Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Argenica Therapeutics's Debt-to-Asset for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	9.541
	=	0.00

Argenica Therapeutics's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	8.621
	=	0.00

Argenica Therapeutics (ASX:AGN) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Argenica Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Argenica Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Argenica Therapeutics (ASX:AGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Argenica Therapeutics Ltd (ASX:AGN) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

117 Broadway, Unit 4, Nedlands, WA, AUS, 6009

Website

https://www.argenica.com.au

Argenica Therapeutics Ltd is engaged in the development and commercialization of novel drug candidates. Its ARG007 drug improves outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicology before commencing Phase 1 clinical trials in humans.

Argenica Therapeutics (ASX:AGN) Headlines

No Headlines